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and optimise the reporting of such evaluations. To our knowledge, there are no such 
published guidelines in Spain. Methods: This guidance was designed with the 
main aim of providing authors with recommendations, in the form of a checklist, to 
optimise design and reporting of EE and BIA to be submitted to the Catalan Health 
System (CatSalut) within its harmonization program for pharmaceutical innova-
tion. Results: For a given evaluation, two separate guidelines with corresponding 
checklists assess its methodology, quality, and reporting based on several dimen-
sions. ConClusions: The steps outlined in this first guidance in Spain, although 
not compulsory, will provide useful practical tips for how to go about designing and 
reporting of an EE or a BIA for pharmaceuticals in Catalonia (Spain).
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objeCtives: In recent years, spending on prescription drugs contributes substan-
tially to the continuous growth in health expenditure which is influenced by both 
a rise in the use of existing drugs and by the adoption of new and expensive drugs. 
However, their effectiveness outside of clinical trial settings is often uncertain at the 
time they gain market approval. This uncertainty may reflect a lack of real-world 
outcomes data, as opposed to clinical trials data, for a typical patient population. 
A risk-sharing agreement is a contract between a drug manufacturer and a health 
care provider/payer to help manage uncertainties regarding the cost and effective-
ness of those drugs and serves the interests of both. Guidelines can be very use-
ful to identify these uncertainties and select the pharmaceuticals which are most 
eligible for such an agreement to be implemented. To our knowledge, there are no 
such published guidelines in Spain. Methods: This guidance was designed with 
the main aim of identifying uncertainties, helping select the pharmaceuticals most 
eligible, and defining best type of risk sharing agreement (RSA) / pay per Results 
scheme (PRS) to be implemented between the Catalan Heath System (CatSalut) 
and health care providers/pharmaceutical companies in Catalonia. Results: For 
a given pharmaceutical, two questionnaires identify and score following four vari-
ables related to main uncertainties involved: (1) efficacy/effectiveness uncertainty; 
(2) budget uncertainty; (3) budget impact; and (4) incremental cost-effectiveness 
ratio (ICER) and willingness to pay. Final score guides the best type of agreement 
to be implemented accordingly. ConClusions: The steps outlined in this first 
guidance in Spain, although not compulsory, will provide useful practical tips for 
how to go about setting up an RSA or PRS in Catalonia (Spain). This guide is not a 
substitute for suitable regulatory or legal advice.
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objeCtives: Patient-centered care (PCC) is a critical component of health care 
management of elderly with multimorbidity, especially for those with co-exist-
ing chronic physical conditions with mental illnesses. However, little is known 
about the association between type of multimorbidity and PCC. The objective of 
this study was to analyze the association between type of multimorbidity and 
PCC. Methods: A retrospective cross-sectional study design was used. Data were 
derived from 2011 Access to Care module of the Medicare Current Beneficiary 
Survey (MCBS). The study sample (N = 10,158) consisted of community-dwelling 
elderly Medicare beneficiaries aged 65 years or older with at least one physical 
chronic condition. Types of multimorbidity (MM) defined as: 1) single physical 
condition (No MM); 2) two or more physical conditions without mental illnesses 
(MM-PI); and 3) both mental and physical conditions (MM-MI&PI). PCC was defined 
using patient-physician communication and patients’ confidence in physician. 
Chi-square tests and logistic regressions were used to test the unadjusted and 
adjusted associations. Results: A lower percentage of elderly Medicare benefi-
ciaries with MM-MI&PI had optimal patient-physician communication (73.5%) 
and high confidence in their physicians (86.1%) as compared to those with No MM 
(79.1% and 90.2%). Without adjustments for health status, elderly with MM-MI&PI 
were less likely to have optimal patient-physician communication (OR = 0.74, 95% 
CI [0.61, 0.88]) and confidence in their physicians (OR = 0.67, 95% CI [0.53, 0.86]) as 
compared to elderly with no MM. The relationship between multimorbidity and 
PCC was not statistically significant after adjusting for general health and func-
tional status. However, those with MM-MI&PI were as likely as those with MM-PI 
to have optimal patient-physician communication and confidence in their physi-
cians. ConClusions: Those with multiple conditions faced poor communication 
and low confidence in doctor as compared to those with single physical condition. 
However, type of multimorbidity was not associated with PCC.
PHP260
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objeCtives: A BCMA system was introduced to the hospital in June 2012. The pur-
pose of this study is to evaluate the impact of the BCMA system on reducing medi-
cation errors and nurse and pharmacist satisfaction with the system. Methods: 
The nurse satisfaction questionnaire and the pharmacist satisfaction question-
naire for the overall system were designed by 8 experts using content validity 
index (CVI). Medication error rates before and after the implementation of the 
allergic rhinitis, cow’s milk allergy, eczema and obesity). Results: Of 100 stud-
ied children 64% were breastfed (BF), while 36% had artificial nutrition (AN), xBF≤  
6months = 48%, xBF> 6months= 52%. Gastroenteritis: xBF = 1,42 diseases/child/life (D/CH/L), 
xAN = 1,64 D/CH/L, xBF≤  6months = 1,84 D/CH/L, xBF> 6months= 1,23D/CH/L. laryngitis: 
xBF= 0,27D/CH/L, xAN = 0,64 D/CH/L, xBF≤  6months = 0,74D/CH/L, xBF> 6months= 0,20D/
CH/L. bronchitis: xBF= 3,73D/CH/L, xAN= 4,86 D/CH/L, xBF≤  6months = 3,89D/CH/L, 
xBF> 6months= 3,34D/CH/L. Pneumonia: xBF= 0,11D/CH/L, xAN = 0,31 D/CH/L, xBF≤  
6months = 0,26D/CH/L, xBF> 6months= 0,03D/CH/L. allergic rhinitis: xBF= 0,16D/CH/L, xAN 
= 0,28 D/CH/L, xBF≤  6months = 0,21D/CH/L, xBF> 6months= 0,11D/CH/L. cow’s milk allergy: 
xBF= 0,11D/CH/L, xAN = 0,17 D/CH/L, xBF≤  6months = 0,16D/CH/L, xBF> 6months= 0,03D/
CH/L. eczema: xBF= 0,09D/CH/L, xAN = 0,42 D/CH/L, xBF≤  6months = 0,21D/CH/L, 
xBF> 6months= 0,03D/CH/L. obesity: xBF= 0,03D/CH/L, xAN = 0,17 D/CH/L, xBF≤  6months 
= 0,05D/CH/L, xBF> 6months= 0,00D/CH/L. ConClusions: Results of the analysis indi-
cated that breastfed children showed less frequent incidence of all of the studied 
diseases compared to children who had artificial nutrition. Breastfeeding and even 
more importantly the duration of breastfeeding has important positive impact on 
child’s health, lower the occurrence of the diseases, frequency of medication use 
and overall total expenditure on health care.
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objeCtives: Objective was to quantify the specialists’ prescription pattern in Iran 
and to point out the prescribing behavioral differences among several special-
ties. Methods: A retrospective cross-sectional study was carried out on the claim 
data. National prescription data were obtained on the basis of the claims that the 
pharmacies submitted to the insurers during 1 year period of the study. More than 
85 million prescriptions were analyzed using “Rx-Analyst” software that is designed 
and applied by National Committee of Rational Use of Medicines in Iran. Specified 
medical specialties were considered and the World Health Organization prescrip-
tion indicators were used to evaluate the physicians’ prescribing behavior. Results: 
Average items per prescription were ranged from 3.68 in cardiologists’ to 2.06 in 
dermatologists’ prescriptions. The highest and the lowest mean price were belonged 
to neurologists’ and ophthalmologists’ prescriptions, respectively. In addition, 45% of 
patients received antibiotics, 41% of patients received injectable form of drugs, and 
23% received corticosteroids. A high tendency toward prescribing corticosteroids and 
antibiotic as well as an injectable form of medicines was observed among general 
physicians. ConClusions: There is an inevitable need to improve prescription hab-
its among different specialties, especially among general practitioners. This causes 
the policymakers to put more emphasis on priorities such as continuous education.
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objeCtives: Monitoring and measuring prescribing patterns can provide valuable 
information regarding the use of medicines and the overall prescribing behavior. 
In Greece, until recently there was no organized system to monitor and record 
prescribing patterns. The aim of this study is to describe prescribing patterns of 
GPs in primary health care. Methods: A prospective cross-sectional study was 
conducted (March–June 2011). Two geographical areas (rural and semirural) in Crete 
and one urban in Athens were randomly selected and all GPs working in these 
areas in public or private practices were invited to participate. Each GP answered a 
structured questionnaire regarding his/her prescribing patterns and collect data on 
100 patients within a specified period. Prescribed drugs and diagnoses were then 
classified according to the ATC classification system and the ICPC-2 classification 
system respectively. Results: 13 GPs (7 from Crete) participated in the study giving 
data for 1202 patients. 84.5% of the patients received a prescription and the mean 
items prescribed were 2.72. At the 12.4% of the total encounters the patient was 
not present while at 9.9% of all encounters the reason was to ask a prescription 
for medicines already bought from the pharmacy. GPs prescribed at the 96.7% and 
97.5% of these cases respectively. Diseases of the circulatory (24.9%), endocrine 
(23.5%) and musculoskeletal (10.4%) systems were the most commonly recorded 
diagnoses. Overall, 62% of all prescribed medicines were from the cardiovascular 
system, alimentary tract and metabolism and nervous system. 4.8% were antibiotics, 
2.7% were injections, 19.9% were launched in the Greek market after 2001, 4% were 
OTCs, 3.7% were narcotics, 10.8% were generics. ConClusions: This preliminary 
descriptive analysis gives an overview of the prescribing patterns of GPs and high-
lights the areas that pharmaceutical policies should be focused. Further analysis is 
needed to identify the factors that determine this behavior.
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objeCtives: Health economic evaluations (EE) and budget impact analysis (BIA) for 
pharmaceuticals are increasingly being used for decision making. Guidelines can be 
very useful to help authors with the use of proper methodology, assess the quality 
